<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the frequency of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> in primary and <z:e sem="disease" ids="C0409983" disease_type="Disease or Syndrome" abbrv="">secondary antiphospholipid syndrome</z:e> (APS); to analyze the clinical and laboratory features characterizing those with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> in a cohort of 538 patients with APS; and to find associated features that would suggest risk factors for <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> in APS </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We analyzed the clinical features of patients with APS who had <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> and compared them to the clinical features of non-<z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e> APS patients </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Of 538 APS patients, 46 (8.6%) had <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">Epilepsy</z:e> was more prevalent among APS secondary to <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) compared to primary APS (13.7% vs 6%; p &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>The patients with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> had a higher prevalence of central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) manifestations including focal ischemic events (<z:hpo ids='HP_0001297'>strokes</z:hpo> or transient ischemic events, 54.3% vs 24.6%; p &lt; 0.0001) and <z:hpo ids='HP_0100576'>amaurosis fugax</z:hpo> (15.2% vs 4.9%; p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>APS patients with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> had a higher frequency of valvular pathology (30.4% vs 14.6%; p &lt; 0.01), <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (43.5% vs 25%; p &lt; 0.05), and <z:hpo ids='HP_0000965'>livedo reticularis</z:hpo> (26.1% vs 11.5%; p &lt; 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>The multivariate logistic regression analysis found <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> as the most significant factor associated with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e>, with an odds ratio (OR) of 4.05 (95% confidence interval, CI: 2.05-8), followed by SLE (OR 1.4, 95% CI 1.2-4.7), and valvular vegetations (OR 2.87, 95% CI 1-8.27) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">Epilepsy</z:e> is common in APS and most of the risk seems to be linked to <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> as manifested by extensive <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement, valvulopathy, and <z:hpo ids='HP_0000965'>livedo reticularis</z:hpo> and to the presence of SLE </plain></SENT>
<SENT sid="8" pm="."><plain>These factors, however, explain only part of the increased occurrence of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> in APS and other causes such as direct immune interaction in the brain should be investigated </plain></SENT>
</text></document>